| Management target | Revenue 25.0% FY28 |
|---|
| Revenue growth | 10% YoY in Q2; H1 revenue up 11.8%. |
|---|---|
| Margins | EBITDA margin stable at 35.5%; potential medium-term 1-2% correction. |
| Demand visibility | Strong recovery in inquiries; pharma R&D pipeline starting to pick up. |
| Management confidence | Balanced; optimistic about recovery despite temporary external headwinds. |
Growth
Revenue grew 10% YoY; H1 revenue up 11.8% to ₹2,278 million.
Outlook
Targets 20-25% CAGR top-line growth; ₹80 Cr FY27 capex budget.
Risks
Logistics costs impacting food exports; long customer decision cycles in pharma.
Earnings Call Transcript filed with NSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹500.70
- Market cap
- ₹2,238 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 28.1×Sector 52.3×
- Promoter holding
- 35.64%-0.03% QoQ
- FII holding
- 5.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Results Update
Vimta Labs reported Q2 FY27 income of ₹1,149 Mn, up 9.9% YoY, and PAT of ₹206 Mn at 17.9% margin. EBITDA margins held steady at 35.5%.
Vimta Labs Investor Presentation: Key Takeaways
Q2 FY27: total income Rs1,149Mn (+9.9% YoY), EBITDA Rs408Mn (35.5% margin), PAT Rs206Mn (17.9% margin, +3.5% YoY). H1 FY27 PAT Rs417Mn (+7.3%).
Vimta Labs Q2 FY27 Results: Net Profit ₹20.6 Cr, Up 3.5% YoY
Vimta Labs Ltd reported revenue from operations of ₹112 Cr (+10.0% YoY) and net profit of ₹20.6 Cr (+3.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.6 Cr · +3.5% YoY
Vimta Labs Board Meeting Date
Vimta Labs will hold a board meeting on 30 October 2026 to consider half-year results. Trading window stays closed from 01 October.
Vimta Labs Other Announcement
Vimta Labs Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.